View More Recent Stories

Nov 28, 2017 05:50AM Ardelyx (ARDX) Reports Licensing Agreement with Kyowa Hakko Kirin for Tenapanor for Cardiorenal Diseases in Japan
Nov 28, 2017 02:00AM Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Nov 21, 2017 06:36AM Ardelyx (ARDX) Updates Development Path for Cardiorenal Pipeline
Nov 21, 2017 06:30AM Ardelyx Announces Updated Development Path for its Cardiorenal Pipeline
Nov 7, 2017 06:30AM Ardelyx Reports Third Quarter 2017 Operating Results and Clinical Progress
Oct 16, 2017 08:12AM Ardelyx (ARDX) Reports Data from Pre-Clinical Studies that Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 16, 2017 08:01AM Ardelyx Announces Tenapanor Reduces Pain Caused by IBS-C Through Inhibition of TRPV-1 Signaling
Oct 11, 2017 04:03PM Ardelyx (ARDX) Says Phase 3 Study of Tenapanor for IBS-C Hit Primary and All Secondary Endpoints
Oct 11, 2017 04:02PM Ardelyx's Pivotal Phase 3 Study of Tenapanor for IBS-C Hits Primary and All Secondary Endpoints to Support NDA Submission in 2018
Aug 9, 2017 06:30AM Ardelyx Focuses Resources on Late-Stage Programs and Reports Second Quarter 2017 Operational Results
Aug 2, 2017 06:30AM Ardelyx Announces Date of Second Quarter Financial Results and Presentation at Wedbush PacGrow Healthcare Conference
May 12, 2017 06:38AM Ardelyx (ARDX) Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C Meets Primary Endpoint
May 12, 2017 06:30AM Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
May 5, 2017 06:30AM Ardelyx Reports First Quarter 2017 Operating Results and Highlights Recent Progress
Apr 18, 2017 06:30AM Ardelyx To Present at Upcoming Spring Medical Meetings
Feb 27, 2017 04:05PM Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
Feb 17, 2017 04:05PM Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
Feb 15, 2017 06:33AM Ardelyx (ARDX) Says Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with ESRD Met Primary Endpoint
Feb 15, 2017 06:30AM Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
View More Recent Stories